FGI-104
FGI-104 is the name of an experimental broad-spectrum antiviral drug, with activity against a range of viruses including Hepatitis B, Hepatitis C, HIV, Ebola virus and Venezuelan equine encephalitis virus. [1]
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
IUPAC name
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C28H30ClN3O3 |
| Molar mass | 492.008 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
Mechanism
The drug acts by inhibiting the protein TSG101, which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice from Ebola virus disease.[2]
References
- Kinch, Michael; Yunus, Abdul; Mao, Hanwen; Lear, Calli; Luo, Guangxiang; Murray, Michael; Huang, Zhuhui; Fesseha, Zena; Chen, Hanson; Olinger, Gene; Goldblatt, Michael (2009). "FGI-104: A Broad-Spectrum Small Molecule Inhibitor of Viral Infection". Antiviral Research. 82 (2): A39–A40. doi:10.1016/j.antiviral.2009.02.082. ISSN 0166-3542. PMC 2776286.
- Janeba, Zlatko (2015). "Development of Small-Molecule Antivirals for Ebola". Medicinal Research Reviews. 35 (6): 1175–1194. doi:10.1002/med.21355. ISSN 0198-6325.
Filoviridae | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||||||||||||||||||||||||||
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.